Johnson & Johnson – Next Billion Dollar Settlement?

by Tony Chicotel, CANHR Staff Attorney

The Wall St. Journal is reporting that the U.S. Attorney’s Office is seeking a settlement of around $1 billion to resolve its investigation of illegal marketing tactics by Johnson & Johnson for its antipsychotic drug Risperdal. The settlement would follow a similar $1.4 billion settlement with pharma-giant Eli Lilly regarding the illegal marketing of Zyprexa as a treatment for dementia in 2009.

The specific allegations against Johnson & Johnson are not known but it is likely they include the promotion of “off-label” Risperdal use, such as for the elderly with dementia.  The settlement is believed to be unrelated to an alleged multi-million dollar kickback scheme between Johnson & Johnson and Omnicare, the nation’s largest dispenser of prescription drugs in nursing homes.


About achicotel

Anthony Chicotel is a staff attorney for CANHR. His areas of expertise include the rights of long-term care residents, nursing home litigation, health care decision-making, and conservatorships.
Print this page.

Responses to CANHR blog postings do not reflect the opinions of CANHR or its staff members.

Leave a Reply